Compare LCNB & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | CCCC |
|---|---|---|
| Founded | 1877 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.5M | 240.3M |
| IPO Year | N/A | 2020 |
| Metric | LCNB | CCCC |
|---|---|---|
| Price | $17.49 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 29.2K | ★ 2.0M |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.23% | N/A |
| EPS Growth | ★ 220.73 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $89,312,000.00 | $30,108,000.00 |
| Revenue This Year | $18.04 | N/A |
| Revenue Next Year | $4.36 | N/A |
| P/E Ratio | $10.09 | ★ N/A |
| Revenue Growth | ★ 19.58 | N/A |
| 52 Week Low | $13.34 | $1.09 |
| 52 Week High | $17.84 | $4.26 |
| Indicator | LCNB | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 34.04 |
| Support Level | $17.07 | $2.00 |
| Resistance Level | $17.59 | $2.69 |
| Average True Range (ATR) | 0.42 | 0.18 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 57.64 | 3.55 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.